ArticleNature communications2023
Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
12.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Structural and functional evolution of IL-1 targeting: From systemic neutralization to bioengineered nanotherapies.Materials today. Bio · 2026Review
- Tumor-Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- HES1 regulates bone marrow mesenchymal stromal cell function by suppressing NFATc2-mediated inflammation.Haematologica · 2026Article
- Succinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression.Nature communications · 2026Article
- Targeting IL-1/IRAK1/4 signaling in acute myeloid leukemia stem cells following treatment and relapse.Leukemia · 2026Article
- Targeting IL-1α Sensitizes HNSCC to PDT by Reversing Hypoxia and NF-κB-Driven Oxidative Stress Resistance.International journal of biological sciences · 2026Article
- IL-1 signaling and inflammasomes in acute myeloid leukemia: mechanisms and therapeutic opportunities.Cellular and molecular life sciences : CMLS · 2025Review
- Multiomic analyses on the contribution of transposable elements to the cis-regulatory landscape of different types of immune cells.BMC genomics · 2025Article
- Modulating immune cell fate and inflammation through CRISPR-mediated DNA methylation editing.Science advances · 2025Article
- Article
- Bone marrow sympathetic neuropathy is a hallmark of hematopoietic malignancies and it involves severe ultrastructural damage.Experimental hematology & oncology · 2025Article
- Comparison the impact of IFN-β alone or in combination with vitamin D on critical pathways involved in AML progression.PloS one · 2025Article
- Publication trends and research hotspots of IL-1: A bibliometric analysis of IL-1 with relevance to anesthesia in highly cited papers from WoSCC.Journal of anesthesia and translational medicine · 2024Article
- Bone marrow inflammation in haematological malignancies.Nature reviews. Immunology · 2024Review
- Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges.Current obesity reports · 2024Review
- IL-1 Family Members in Bone Sarcomas.Cells · 2024Review
- Identification and Validation of Novel Metastasis-Related Immune Gene Signature in Breast Cancer.Breast cancer (Dove Medical Press) · 2024Article
- NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy.Cell reports. Medicine · 2023Article
- Bibliometric analysis of monoclonal antibodies for atherosclerosis.Human vaccines & immunotherapeutics · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
22 authors at 5 institutions in 3 countries.
Alicia Villatoro *Stem Cells, Ageing and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH2 building level 10, 9019, Tromsø, Norway.
Vincent Cuminetti *Stem Cells, Ageing and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH2 building level 10, 9019, Tromsø, Norway.ORCID http://orcid.org/0000-0001-8396-710X
Aurora BernalStem Cells, Ageing and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH2 building level 10, 9019, Tromsø, Norway.ORCID http://orcid.org/0000-0002-5741-7865
Carlos TorrojaBioinformatics Unit, Fundación Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029, Madrid, Spain.ORCID http://orcid.org/0000-0001-8914-3400
Itziar CossíoArea of Cell and Developmental Biology, CNIC, 28029, Madrid, Spain.
Alberto BenguríaGenomics Unit, CNIC, 28029, Madrid, Spain.
Marc FerréStem Cells, Ageing and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH2 building level 10, 9019, Tromsø, Norway.
Joanna KoniecznyStem Cells, Ageing and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH2 building level 10, 9019, Tromsø, Norway.
Enrique VázquezGenomics Unit, CNIC, 28029, Madrid, Spain.ORCID http://orcid.org/0000-0003-1157-2592
Andrea RubioArea of Cell and Developmental Biology, CNIC, 28029, Madrid, Spain.
Peter UtnesStem Cells, Ageing and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH2 building level 10, 9019, Tromsø, Norway.
Almudena TelloStem Cells, Ageing and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH2 building level 10, 9019, Tromsø, Norway.
Xiaona YouMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI, 53705, USA.ORCID http://orcid.org/0000-0001-9996-1466
Christopher G FentonGenomics Support Center Tromsø, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH building level 9, 9019, Tromsø, Norway.
Ruth H PaulssenGenomics Support Center Tromsø, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH building level 9, 9019, Tromsø, Norway.ORCID http://orcid.org/0000-0001-6436-4143
Jing ZhangMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI, 53705, USA.ORCID http://orcid.org/0000-0003-1194-0666
Fátima Sánchez-CaboBioinformatics Unit, Fundación Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029, Madrid, Spain.ORCID http://orcid.org/0000-0003-1881-1664
Ana DopazoGenomics Unit, CNIC, 28029, Madrid, Spain.ORCID http://orcid.org/0000-0002-4910-1684
Anders VikDepartment of Hematology, University Hospital of North Norway, 9019, Tromsø, Norway.
Endre AnderssenGenomics Support Center Tromsø, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH building level 9, 9019, Tromsø, Norway.ORCID http://orcid.org/0000-0002-2995-6335
Andrés HidalgoArea of Cell and Developmental Biology, CNIC, 28029, Madrid, Spain.
Lorena ArranzStem Cells, Ageing and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH2 building level 10, 9019, Tromsø, Norway. lorena.arranz@uit.no.ORCID http://orcid.org/0000-0002-5896-4238
UiT The Arctic University of Norway · NOSpanish National Centre for Cardiovascular Research · ESUniversity of Wisconsin–Madison · USUniversity Hospital of North Norway · NOUniversity of Oslo · NO
Funding
The role of TCOF1 in germline predisposition to and in leukemic transformation of chronic myelomonocytic leukemiaR01CA152108 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Jing Zhang · 2011 to 2026
$5.4MNCI NIH HHS R01 CA152108
Abstract
Here we explored the role of interleukin-1β (IL-1β) repressor cytokine, IL-1 receptor antagonist (IL-1rn), in both healthy and abnormal hematopoiesis. Low IL-1RN is frequent in acute myeloid leukemia (AML) patients and represents a prognostic marker of reduced survival. Treatments with IL-1RN and the IL-1β monoclonal antibody canakinumab reduce the expansion of leukemic cells, including CD34
Indexed as
Leukemia, Myeloid, AcuteReceptors, Interleukin-1Antigens, CD34Bone MarrowCell ProliferationHumansAntigens, CD34Receptors, Interleukin-1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.